Payment overview · 2025
General Payments
$279.79
13 reported records · 7 companies
Healthcare provider profile · identity verified
Chad Lauer
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · SENECA, PA · NPI 1699703694
Verified facts
What the public records show
CMS Open Payments records show Chad Lauer received $279.79 in general payments during 2025 across 13 reported records.
Alkermes, Inc. accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $82.95 | 29.6% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $55.36 | 19.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.06 | 17.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.25 | 14.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.99 | 7.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.46 | 6.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.72 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $279.79 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $82.95 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $48.06 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.25 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $36.67 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 199 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
199 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
199 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 563 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 419 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 328 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 289 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 280 | 79 |
| Lisinopril | Lisinopril | 236 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 218 | 66 |
| Losartan Potassium | Losartan Potassium | 204 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 57 |
| Eliquis | Apixaban | 199 | 43 |
| Trazodone Hcl | Trazodone Hcl | 194 | 41 |
| Gabapentin | Gabapentin | 190 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 181 | 14 |
| Omeprazole | Omeprazole | 168 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 45 |
| Valsartan | Valsartan | 147 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 44 |
| Buspirone Hcl | Buspirone Hcl | 132 | 22 |
| Ozempic | Semaglutide | 132 | 18 |
| Potassium Chloride | Potassium Chloride | 119 | 30 |
| Sertraline Hcl | Sertraline Hcl | 117 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 34 |
| Montelukast Sodium | Montelukast Sodium | 112 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 29 |
| Jardiance | Empagliflozin | 106 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 27 |
| Mirtazapine | Mirtazapine | 104 | 22 |
| Metformin Hcl | Metformin Hcl | 103 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 18 |
| Metformin Hcl Er | Metformin Hcl | 99 | 28 |
| Clonidine Hcl | Clonidine Hcl | 95 | 22 |
| Simvastatin | Simvastatin | 89 | 28 |
| Carvedilol | Carvedilol | 86 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 84 | 15 |
| Prednisone | Prednisone | 83 | 64 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 82 | 67 |
| Famotidine | Famotidine | 82 | 23 |
| Lorazepam | Lorazepam | 80 | 18 |
| Bupropion Xl | Bupropion Hcl | 79 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 79 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 37 |
| Lamotrigine | Lamotrigine | 78 | 14 |
| Furosemide | Furosemide | 77 | 25 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 74 | 19 |
| Meloxicam | Meloxicam | 69 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 64 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 16 |
| Methocarbamol | Methocarbamol | 62 | 20 |
| Spironolactone | Spironolactone | 58 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | 17 |
| Allopurinol | Allopurinol | 56 | 15 |
| Synthroid | Levothyroxine Sodium | 56 | 15 |
| Tramadol Hcl | Tramadol Hcl | 53 | 13 |
| Ezetimibe | Ezetimibe | 52 | 20 |
| Benztropine Mesylate | Benztropine Mesylate | 51 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 51 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 16 |
| Meclizine Hcl | Meclizine Hcl | 49 | 15 |
| Warfarin Sodium | Warfarin Sodium | 48 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 11 |
| Irbesartan | Irbesartan | 44 | 11 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | 17 |
| Dutasteride | Dutasteride | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 14 |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 42 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | 14 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Ranolazine Er | Ranolazine | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Azithromycin | Azithromycin | 32 | 29 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 31 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Fentanyl | Fentanyl | 29 | suppressed |
| Paliperidone Er | Paliperidone | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Jantoven | Warfarin Sodium | 25 | suppressed |
| Prolia | Denosumab | 25 | 16 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Clonazepam | Clonazepam | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 12 |
| Atenolol | Atenolol | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Tradjenta | Linagliptin | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Droplet Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tresiba | Insulin Degludec | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Alogliptin | Alogliptin Benzoate | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $279.79 · 13 records | Alkermes, Inc. | ARISTADA, Auvelity, CAPLYTA, COBENFY, ELIQUIS, LYBALVI, NURTEC ODT, VOQUEZNA, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error